Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: A one-year study

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 942-950

  Ajeganova, Sofia ^a   Fiskesund, Roland ^b   De Faire, Ulf ^a   Hafström, Ingiäld ^a   Frostegård, Johan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibodies against phosphorylcholine; Apolipoprotein A1; Biological therapy; Remission; Rheumatoid arthritis; Rituximab; Tumour necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; APOLIPOPROTEIN; APOLIPOPROTEIN A1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHORYLCHOLINE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BIOLOGICAL THERAPY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOTURBIDIMETRY; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; TURBIDIMETRY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; APOLIPOPROTEINS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857573905     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. WEINBLATT ME, KURITZKY L: RAPID: rheumatoid arthritis. J Fam Pract 2007;56:S1-7; quiz S8.
2. MEUNE C, TOUZE E, TRINQUART L, ALLAN-ORE Y: Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13.
3. PETERS MJ, VAN HALM VP, VOSKUYL AE et al.: Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
4. FROSTEGARD J: Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005;25:1776-85. (Pubitemid 41243443)
5. GONZALEZ-JUAN ATEY C, TESTA A, GARCIA-CASTELO A, GARCIA-PORRUA C, LLORCA J, GONZALEZ-GAY MA: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing longterm treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51:447-50. (Pubitemid 38725146)
6. BARNABE C, MARTIN BJ, GHALI WA: Systematic review and meta-analysis: Anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9.
7. WESTLAKE SL, COLEBATCH AN, BAIRD J et al.: Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518-31.
8. VAN DOORNUM S, MCCOLL G, WICKS IP: Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1428-32. (Pubitemid 41631868)
9. MAKI-PETAJA KM, HALL FC, BOOTH AD et al.: Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92. (Pubitemid 44386483)
10. GARCES SP, PARREIRA SANTOS MJ, VINA-GRE FM, ROQUE RM, DA SILVA JA: Antitumour necrosis factor agents and lipid profile: a class effect? Ann Rheum Dis 2008;67:895-6. (Pubitemid 351829399)
11. POLLONO EN, LOPEZ-OLIVO MA, LOPEZ JA, SUAREZ-ALMAZOR ME: A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:947-55.
12. DORNER T, RADBRUCH A, BURMESTER GR: B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009;5:433-41.
13. WU R, DE FAIRE U, LEMNE C, WITZTUM JL, FROSTEGARD J: Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999;33:53-9. (Pubitemid 29061841)
14. BINDER CJ, SILVERMAN GJ: Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 2005;26:385-404. (Pubitemid 40468892)
15. SHOENFELD Y, WU R, DEARING LD, MATSU-URA E: Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8. (Pubitemid 39453000)
16. KEREKES G, SOLTESZ P, DER H et al.: Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705-10.
17. JIN T, BOKAREWA M, AMU S, TARKOWSKI A: Impact of short-term therapies with biologies on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol 2009;27:491-4.
18. GRONLUND H, HALLMANS G, JANSSON JH et al.: Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a populationbased cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 2009;16:382-6.
19. ELKAN AC, SJOBERG B, KOLSRUD B, RING-ERTZ B, HAFSTROM I, FROSTEGARD J: Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. Arthritis Res Ther 2008;10:R34.
20. DE FAIRE U, SU J, HUA X et al.: Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 2010;34:73-9.
21. FISKESUND R, STEGMAYR B, HALLMANS G et al.: Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 2010;41:607-12.
22. SU J, GEORGIADES A, WU R, THULIN T, DE FAIRE U, FROSTEGARD J: Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006;188:160-6. (Pubitemid 44160704)
23. SU J, HUA X, CONCHA H, SVENUNGSSON E, CEDERHOLM A, FROSTEGARD J: Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 2008;47:1144-50. (Pubitemid 352038217)
24. ANANIA C, GUSTAFSSON T, HUA X et al.: Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010;12:R214.
25. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
26. FRANSEN J, CREEMERS MC, VAN RIEL PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. (Pubitemid 39359299)
27. EKDAHL C, EBERHARDT K, ANDERSSON SI, SVENSSON B: Assessing disability in patients with rheumatoid arthritis. use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
28. SJOBERG BG, SU J, DAHLBOM I et al.: Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009;203:528-32.
29. BRILES DE, FORMAN C, HUDAK S, CLAFLIN JL: Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982;156:1177-85. (Pubitemid 12036279)
30. HARNETT W, HARNETT MM: Phosphorylcholine: friend or foe of the immune system? Immunol Today 1999;20:125-9. (Pubitemid 29130341)
31. CALIGIURI G, KHALLOU-LASCHET J, VAN DAELE M et al.: Phosphorylcholine- targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007;50:540-6. (Pubitemid 47126777)
32. FARIA-NETO JR, CHYU KY, LI X et al.: Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006;189:83-90. (Pubitemid 44468069)
33. FROSTEGARD J, TAO W, GEORGIADES A, RASTAM L, LINDBLAD U, LINDEBERG S: Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond) 2007;4:7.
34. FROSTEGARD J: Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol 2010;134:47-54.
35. EDWARDS U, CONSTANTINESCU CS: Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 2009;8:182-90.
36. CUGNO M, INGEGNOLI F, GUALTIEROTTI R, FANTINI F: Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 2010;8:285-92.
37. GONZALEZ-JUANATEY C, LLORCA J, VAZQUEZ-RODRIGUEZ TR, DIAZ-VARELA N, GARCIA-QUIROGA H, GONZALEZ-GAY MA: Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008;59:1821-4.
38. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45. (Pubitemid 24030569)
39. VAN LEEUWEN M, DAMOISEAUX J, DUIJ-VESTIJN A, TERVAERT JW: The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 2009;9:53-7.
40. CORNEC D, AVOUAC J, YOUINOU P, SARAUX A: Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009;8:515-9.
41. CAMBRIDGE G, LEANDRO MJ, TEODORES-CU M et al.: B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006;54:3612-22. (Pubitemid 44737173)
42. TATE J, WARD G: Interferences in immunoassay. Clin Biochem Rev 2004;25:105-20.
43. ATZENI F, TURIEL M, CAPSONI F, DORIA A, MERONI P, SARZI-PUTTINI P: Autoimmunity and anti-TNF-alpha agents. Ann NY Acad Sci 2005;1051:559-69.
44. CHOY E, SATTAR N: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
45. FROSTEGARD J, NILSSON J, HAEGERSTRAND A, HAMSTEN A, WIGZELL H, GIDLUND M: Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990;87:904-8.
46. FROSTEGARD J, WU R, GISCOMBE R, HOLM G, LEFVERT AK, NILSSON J: Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb 1992;12:461-7.
47. WINYARD PG, TATZBER F, ESTERBAUER H, KUS ML, BLAKE DR, MORRIS CJ: Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1993;52:677-80. (Pubitemid 23280438)
48. SUZUKI T, KOHNO H, HASEG AWA A et al.: Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 2002;35:347-53. (Pubitemid 35247942)
49. ITABE H, UEDA M: Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007;14:1-11.